Accelerate Diagnostics (AXDX) Getting Somewhat Favorable Press Coverage, Report Finds
Media headlines about Accelerate Diagnostics (NASDAQ:AXDX) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Accelerate Diagnostics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.0317443323042 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Accelerate Diagnostics, Inc. (NasdaqCM:AXDX) and Houghton Mifflin Harcourt Company (NasdaqGS:HMHC) Value … – Evergreen Caller (evergreencaller.com)
- Company Spotlight: Accelerate Diagnostics – Nasdaq (nasdaq.com)
- Does Ironwood Pharmaceuticals, Inc. (IRWD)’s current closing price competes the market? – ClickLancashire (clicklancashire.com)
- Accelerate Diagnostics, Inc. (AXDX) -6.03% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Accelerate Diagnostics, Inc. :AXDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 (finance.yahoo.com)
A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. BTIG Research reiterated a “buy” rating and set a $34.00 price objective on shares of Accelerate Diagnostics in a research report on Wednesday, May 17th. ValuEngine downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $32.00 price objective (up previously from $30.00) on shares of Accelerate Diagnostics in a research report on Monday, June 5th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $33.00.
Shares of Accelerate Diagnostics (NASDAQ:AXDX) traded down 0.22% during trading on Wednesday, reaching $22.65. The company had a trading volume of 172,529 shares. The firm’s 50 day moving average price is $25.40 and its 200 day moving average price is $25.80. The firm’s market capitalization is $1.25 billion. Accelerate Diagnostics has a 12 month low of $19.20 and a 12 month high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.40 million. Equities analysts predict that Accelerate Diagnostics will post ($1.20) EPS for the current year.
In other Accelerate Diagnostics news, insider Steven Reichling sold 30,000 shares of Accelerate Diagnostics stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $28.90, for a total transaction of $867,000.00. Following the transaction, the insider now directly owns 30,700 shares in the company, valued at approximately $887,230. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jack W. Schuler acquired 23,400 shares of the stock in a transaction on Monday, August 14th. The shares were purchased at an average price of $21.35 per share, for a total transaction of $499,590.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 161,600 shares of company stock worth $3,461,560. Corporate insiders own 51.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Accelerate Diagnostics (AXDX) Getting Somewhat Favorable Press Coverage, Report Finds” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/30/accelerate-diagnostics-axdx-getting-somewhat-favorable-press-coverage-report-finds.html.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.